Ascension has quietly built out a strikingly unusual private equity operation worth more than $1 billion, a STAT investigation has found. | Continue reading
The new Covid pills from Merck and Pfizer offer a ton of promise. But there’s plenty we still don’t know about how well they work. | Continue reading
With whole genome sequencing, doctors in the U.K. were able to determine diagnoses for more people with rare diseases. | Continue reading
Overall, 29.1% of patients in the highest-dose group were in remission three weeks after treatment, compared to 7.6% in the control group. | Continue reading
In the debate about the origin of Covid-19, preventing future pandemics by applying lessons learned has far more value than assigning blame. | Continue reading
An experimental antiviral pill from Pfizer reduced Covid patients' risk of death and hospitalization by 89% in a large study. | Continue reading
An experimental antiviral pill from Pfizer reduced Covid patients' risk of death and hospitalization by 89% in a large study. | Continue reading
An experimental antiviral pill from Pfizer reduced Covid patients' risk of death and hospitalization by 89% in a large study. | Continue reading
An FDA advisory panel voted in favor of authorizing the Pfizer/BioNTech Covid-19 vaccine for children between the ages of 5 and 11. | Continue reading
A bottle of the room spray sold at Walmart was found to contain bacteria that causes melioidosis, a serious, sometimes fatal infection. | Continue reading
The chief executive Athira Pharma left the company after papers she published as a student were found to contain altered research. | Continue reading
In a clinical trial, a subtle electrical shock in the patient's brain interfered with the spirals of her lifelong depression, scientists said. | Continue reading
The data on the drug, developed in partnership with Ridgeback Biotherapeutics, could be a possible game-changer for treatment of patients. | Continue reading
Health equity researchers say they welcome new interest — and white allies — but many are troubled by "health equity tourists." | Continue reading
U.S. deaths make up roughly 14% of the nearly 4.7 million fatalities that have been reported worldwide in this pandemic to date. | Continue reading
The two-dose regimen prevented 75% of moderate to severe Covid cases in all countries where it was tested — and 94% of such cases in the U.S. | Continue reading
The advisory committee recommended against booster doses for most Americans but for them for older and high-risk Americans. | Continue reading
The procedure aims to restore proprioception, the ability to sense where our limbs are in space and how fast and forcefully they’re moving. | Continue reading
STAT was granted a rare look inside Pfizer’s vaccine research labs, which have remained a place of frenetic activity through the pandemic. | Continue reading
J&J's HIV vaccine, using the same technology as its COVID vaccine, failed to meet its goal of reducing the chance of HIV infection by 50%. | Continue reading
Voices on the extreme right and extreme left are drowning out opportunities for conversations we should be having about unvaccinated people. | Continue reading
Moderna Therapeutics, the most highly valued private company in biotech, has run into troubling safety problems with its most ambitious therapy, STAT found. | Continue reading
We can’t predict the next coronavirus variant. But there are some fundamental principles that explain why the virus has morphed as it has. | Continue reading
Many flat-out challenged the need for booster doses at this time. Others questioned the morality of the decision. | Continue reading
By spurring testing and contact tracing, local Covid-19 outbreaks can identify at-risk individuals and help them choose to be vaccinated. | Continue reading
“The field got stuck in a cul-de-sac of just looking at [the same drugs]” for treating depressed patients, said one depression researcher. | Continue reading
Families of kids with a rare disease have waited years for a treatment. In seconds, an AI tool pinpointed an unexpected target: ketamine. | Continue reading
Opioid settlement funds must go to building the public health systems needed to respond to the opioid crisis and prevent future addiction. | Continue reading
The decline, from a peak of 96% efficacy, could fuel Pfizer’s case that a third dose will eventually be required. | Continue reading
A STAT investigation found several AI algorithms developed by Epic are delivering inaccurate information on seriously ill patients. | Continue reading
Why is Delta such a big deal? What does it mean for the vaccines? Answers to your burning questions about the next phase of the pandemic. | Continue reading
The advance promises to unlock the new insights into human biology, aiding in the study of everything from immune systems to skin cancer. | Continue reading
Explainable artificial intelligence may not add transparency to black-box AI and machine learning algorithms and in some instances can hurt. | Continue reading
An ad for Aduhelm, the new Alzheimer's drug, called "When Memory Fades" offers the kind of misinformation the surgeon general warns about. | Continue reading
As emergency provisions end, patients are scrambling — in some cases, driving across state lines — to keep their telehealth appointments. | Continue reading
Death rates are declining for more than half of the most common forms of cancer in the U.S., according to a new report. | Continue reading
Smoking menthol cigarettes is associated with reduced success in quitting among people who smoke nearly every day, a new study finds. | Continue reading
In this time of transition, we’re back with our annual STAT summer book list — and this time we’ve thrown podcasts in the mix too. | Continue reading
When Aduhelm’s prospects appeared dead, Biogen mounted a secret campaign to resurrect the drug and convince the FDA to approve it. | Continue reading
Hundreds of hospitals have used an Epic algorithm to predict sepsis. New research finds it missed two-thirds of cases in one health system. | Continue reading
A new collaboration between the Broad Institute and MD Anderson aims to develop novel models that can help scientists study rare cancers. | Continue reading
A new STAT analysis shows that more than two-thirds of Congress cashed a check from the pharmaceutical industry ahead of the 2020 election. | Continue reading
The trial results put the Novaxax vaccine in the same efficacy ballpark as the mRNA vaccines produced by Pfizer-BioNTech and Moderna. | Continue reading
More children and adolescents are experiencing chronic symptoms after Covid-19 even as the pandemic ebbs in the U.S. | Continue reading
Experts say fatal flaws in the methodology of many machine learning papers make it hard to have faith in published claims. | Continue reading
The claim, if confirmed, surpasses the achievement laid out by leaders from the Human Genome Project and Celera Genomics in 2000. | Continue reading
The panel revised its view on studies that would take embryos beyond 14 days, moving them from the “absolutely not” category to a “maybe.” | Continue reading
The genetically modified neurons became stand-ins for the photoreceptors he had lost many years before to retinitis pigmentosa. | Continue reading